We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FOXF:NASDAQFox Factory Holding Corp. Analysis

Data as of 2026-05-30 - not real-time

$18.04

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Fox Factory (FOXF) is trading at $18.04, comfortably above its 20‑day SMA (≈$17.14) and 50‑day SMA (≈$17.07) but still below the 200‑day SMA (≈$19.86), indicating a short‑term up‑trend within a longer‑term down‑trend. The RSI sits at 56.7, suggesting neutral momentum, while the MACD histogram is positive and the signal line is bearish, delivering a bullish MACD crossover. Volatility is elevated at over 52% for the past 30 days and beta is 1.41, pointing to a stock that moves sharply with the market. Fundamentals show modest revenue growth (≈3.8%) and a gross margin of 29.7%, yet profitability remains weak with a -20% net margin and a trailing EPS of -$7.16, though forward EPS is projected at $1.76. The balance sheet is strained: debt‑to‑equity exceeds 119% and ROE is –37.5%, while cash balances are modest relative to debt. The market has priced in a 23.8% upside to the consensus target of $22, and the forward P/E of 10.3 is attractive for a cyclical consumer play. Recent earnings beat, with Q1 revenue of $368.7 M (+3.9% YoY) and adjusted EBITDA of $35.7 M, reinforced the 2026 outlook and highlighted $50 M of cost‑saving initiatives. Sentiment is at “Extreme Greed” on the fear‑greed index, but the high volatility and debt load temper enthusiasm. Overall, the stock offers a blend of short‑term technical upside and long‑term value concerns, making disciplined positioning essential.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Q1 earnings beat and strong EBITDA
  • Bullish MACD crossover with price above short‑term SMAs
  • Technical support at $15.69 offering downside cushion

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • Reaffirmed 2026 sales and EBITDA guidance
  • $50 M cost‑saving program improving margin trajectory
  • Forward P/E of ~10 suggesting attractive valuation relative to peers

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • High debt‑to‑equity ratio and negative ROE signal balance‑sheet risk
  • Consumer‑cyclical exposure makes earnings sensitive to economic cycles
  • Brand strength and diversified product lines provide a defensive moat

Key Metrics & Analysis

Financial Health

Revenue Growth3.80%
Profit Margin-20.25%
P/E Ratio10.3
ROE-37.54%
ROA1.97%
Debt/Equity119.56
P/B Ratio1.1
Op. Cash Flow$44.2M
Free Cash Flow$47.5M

Technical Analysis

TrendNeutral
RSI56.7
Support$15.69
Resistance$20.98
MA 20$17.14
MA 50$17.07
MA 200$19.86
MACDBullish
VolumeDecreasing
Fear & Greed Index94.07

Valuation

Fair Value$0.16
Target Price$22.33
Upside/Downside23.80%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.41
Volatility52.49%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.